Article · 2 Jun 2026
Conference abstract
Novel combinatorial approach with multiple therapeutic genes and clinically feasible gene delivery method improves cancer gene therapy in pre-clinical animal model
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Triple Negative Breast Cancer (TNBC) is highly metastatic, and an obdurate cancer subtype that is not amenable to current chemotherapy regimens used in the clinic. Palliative chemotherapy with a combination of cyclophosphamide, paclitaxel, and cisplatin or carboplatin and doxorubicin is the only option currently available for treating patients with advanced stage metastatic TNBC. The use of high doses of chemotherapeutics often leads to the development of drug resistant cancer, and also can result in severe systemic toxicity. Gene-Directed Enzyme Prodrug Therapy (GDEPT) is a superior gene therapy method for treating cancers, proven to be effective against many sub-types of cancers, and is currently in various stages of clinical trials. Gene therapy utilizing a single enzyme/prodrug combination targeting a single cellular mechanism requires a significant level of overexpression of delivered therapeutic transgene in order to accomplish therapeutic response. Hence, to overcome this obstacle, we developed molecularly targeted multi-gene therapeutic system in combination with a clinically feasible delivery mechanism, which, when delivered targets several cellular mechanisms to kill cancer cells while simultaneously reprogramming cancer cells to evade from treatment response and in developing drug-resistant phenotypes. In addition, the genes that we use are holding the property of monitoring by noninvasive molecular imaging, which facilitates the monitoring the expression level of therapeutic genes in living animals to correlate with the therapeutic outcome. Moreover, target specific delivery and expression of therapeutic genes to cancer cells is another challenging task, which limits the efficiency of gene therapy. Hence, we are currently combining cancer specific expression of molecularly targeted multilevel therapeutic genes delivered by a minimally toxic nanoformulation, which efficiently deliver DNA for cancer gene therapy in vivo. This strategy will lead to a new generation of gene therapy system in combination with an efficient gene delivery system, which would change current treatment strategy for triple negative breast cancer, and can lead to a paradigm shift in cancer gene therapy.
Keywords
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Stem Cell Research & Therapy.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Stem Cell Research & Therapy
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Ramasamy Paulmurugan”
